VALFIX Medical Inc., a robotic transcatheter solutions company, pioneering a less invasive approach to mitral valve repair, today announced the allowance of three new patents in the United States, Israel and the European Union. These new patents, which focus on the company’s proprietary anchoring and locking technologies, bring VALFIX Medical’s total intellectual property portfolio to 12 granted patents, with many more pending globally.
“The issuance of these three new patents is an important milestone for VALFIX Medical and a testament to our team’s unwavering commitment to innovation,” said Mr. Eli Bar, CEO of VALFIX Medical. “The anchor and lock technologies are vital to the clinical success of our transcatheter approach, providing the enhanced stability and long-term durability necessary for a safe and effective treatment. This expanded IP portfolio solidifies our strategic position in the market and reinforces the confidence of our investors and partners as we advance toward clinical trials.”
The U.S. patent (US1,223,931) protects our innovative locking method, which enables a secure and durable attachment of the annuloplasty ring to the mitral annulus. The method employs a unique self-locking mechanism that is activated after ring placement, providing enhanced stability and confidence in the long-term effectiveness of the procedure.
The Israeli patent (IL284329) also protects our innovative anchor design which features, radially expanding stabilizing loops, designed to provide a secure, multi-point fixation by expanding against the heart tissue upon deployment.”
The EU patent (EP3448317) protects the core apparatus of our transcatheter heart valve repair system. This includes an innovative delivery system that houses multiple tissue anchors within an expandable annular structure.